BCM
PCRX icon

BlueCrest Capital Management’s Pacira BioSciences PCRX Stock Holding History

BlueCrest Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,131
Closed -$695K – 1284
2018
Q3 		$695K Sell
14,131
-2,446
-15% -$106K 0.02% 592
2018
Q2 		$531K Buy
16,577
+2,421
+17% +$83.6K 0.01% 804
2018
Q1 		$441K Buy
14,156
+621
+5% +$22.1K 0.01% 842
2017
Q4 		$618K Buy
13,535
+1,007
+8% +$39.9K 0.02% 480
2017
Q3 		$470K Buy
12,528
+2,158
+21% +$86.8K 0.02% 533
2017
Q2 		$495K Buy
+10,370
New +$481K 0.02% 589

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return